Adicet Bio Past Earnings Performance
Past criteria checks 0/6
Adicet Bio's earnings have been declining at an average annual rate of -39.2%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 6.1% per year.
Key information
-39.2%
Earnings growth rate
29.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 6.1% |
| Return on equity | -83.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate
Feb 01
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?
Dec 07Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?
Aug 07Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Apr 20Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation
Dec 20Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio
Oct 17Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?
Oct 04Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term
Aug 16Adicet Bio: A First Take
Jul 22Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Jul 07Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit
May 15We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate
Mar 18Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate
Feb 09Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management
Dec 28Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Dec 16Revenue & Expenses BreakdownBeta
How Adicet Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -143 | 27 | 106 |
| 30 Sep 23 | 0 | -143 | 26 | 106 |
| 30 Jun 23 | 0 | -115 | 26 | 97 |
| 31 Mar 23 | 0 | -105 | 26 | 85 |
| 31 Dec 22 | 25 | -70 | 26 | 71 |
| 30 Sep 22 | 30 | -56 | 26 | 61 |
| 30 Jun 22 | 34 | -48 | 25 | 56 |
| 31 Mar 22 | 39 | -36 | 23 | 50 |
| 31 Dec 21 | 10 | -62 | 22 | 48 |
| 30 Sep 21 | 10 | -55 | 14 | 42 |
| 30 Jun 21 | 9 | -56 | 16 | 39 |
| 31 Mar 21 | 12 | -54 | 19 | 38 |
| 31 Dec 20 | 18 | -37 | 16 | 34 |
| 30 Sep 20 | 14 | -34 | 20 | 31 |
| 30 Jun 20 | 4 | -34 | 14 | 29 |
| 31 Mar 20 | 0 | -28 | 9 | 26 |
| 31 Dec 19 | 1 | -28 | 9 | 24 |
| 31 Dec 18 | 8 | -9 | 8 | 15 |
Quality Earnings: ACET is currently unprofitable.
Growing Profit Margin: ACET is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACET is unprofitable, and losses have increased over the past 5 years at a rate of 39.2% per year.
Accelerating Growth: Unable to compare ACET's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACET is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: ACET has a negative Return on Equity (-83.83%), as it is currently unprofitable.